Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Business & Industry
- Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
- Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab
- AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
- GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
Research & Development
- Nanotech strategy shows promise for treating autoimmune disease
- The first potent COQ8 inhibitor targets ubiquinone biosynthesis
- AI tailors artificial DNA for future drug development
- Remdesivir reduces COVID-19 mortality in a real-world setting
- Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
- Cryptic drug-binding sites discovered in the dance
- Unusual type of antibody shows ultrapotent activity against Zika
Conferences & Events
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
Regulatory Affairs
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals